ArticleJHLT open2024
Evaluation of the tacrolimus drug interaction with voriconazole vs clotrimazole in heart transplant recipients.
Article in JHLT open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antifungal prophylaxis postheart transplant (HT) may include voriconazole or clotrimazole, which interact with tacrolimus. There is no guidance for tacrolimus adjustment when transitioning from voriconazole to clotrimazole; therefore, this study evaluates tacrolimus concentration/dose (C/D) ratio on voriconazole compared to clotrimazole. This retrospective, single-center analysis included HT recipients (February 2016-September 2021) who received tacrolimus and voriconazole followed by clotrimazole. Tacrolimus C/D ratio was compared on voriconazole vs clotrimazole, and on clotrimazole vs postantifungal discontinuation. Seventy-two patients were included. The median (interquartile range) tacrolimus C/D ratio was 41% (1.7-fold) lower after transition from voriconazole to clotrimazole [5.1 (3.5, 7.7) vs 3.0 (2.0, 4.6) (ng/ml)/(mg/day),
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.